← Back to home
Comparison · Analytics

DoseFinding vs OpenObserve

A side-by-side editorial comparison of DoseFinding and OpenObserve — release velocity, themes, recent moves, and the top alternatives to consider.

DoseFinding vs OpenObserve: at a glance

FeatureDoseFindingOpenObserve
SectorAnalyticsAnalytics
Velocity score0.06.3
Sparks · 30d01
Top themesdose-response, mcp-mod, clinical-trials, model-averagingobservability, synthetic-monitoring, mcp, incident-management
Last editorial update4d ago1d ago
WebsiteVisit →Visit →

What is DoseFinding?

New stewardship at openpharma, then two releases adding the methods MCP-Mod was missing

DoseFinding implements MCP-Mod and related dose-response methodology for clinical trial design and analysis. In 2024 it changed hands — Marius Thomas took over as maintainer, Novartis was recorded as copyright holder and funder, and the package moved to the openpharma GitHub organisation with roxygen documentation and a proper NEWS file. The two releases since have added substantive methodology: model averaging for dose-response fitting in 1.3-1, and conditional and predictive power for interim analyses in 1.4-1.

Read the full DoseFinding trajectory →

What is OpenObserve?

After its largest release, OpenObserve is patching the seams.

v0.92.0 landed on 7 August with 836 commits and three new product surfaces - synthetic monitoring, Workflows v1, and an expanded AI observability set - after a long RC series. The two releases since are small: v0.92.1 fixed alert HAVING clause typing and put the MCP server setup page on the OSS build, and v0.92.2 adds a compactor delay setting and backports an MCP 404 fix for deployments running under a base URI. The 0.91 line is still receiving its own backports.

Read the full OpenObserve trajectory →

DoseFinding vs OpenObserve: editorial side-by-side

D
DoseFinding
ANALYTICS
0.0

New stewardship at openpharma, then two releases adding the methods MCP-Mod was missing

◆ Current state

DoseFinding implements MCP-Mod and related dose-response methodology for clinical trial design and analysis. In 2024 it changed hands — Marius Thomas took over as maintainer, Novartis was recorded as copyright holder and funder, and the package moved to the openpharma GitHub organisation with roxygen documentation and a proper NEWS file. The two releases since have added substantive methodology: model averaging for dose-response fitting in 1.3-1, and conditional and predictive power for interim analyses in 1.4-1.

◆ Where it's heading

The pattern before the handover was maintenance — R-devel compliance, a bug fix, a link. After it, each release carries a named methodological addition with an acknowledged contributor, plus documentation to match: a longitudinal analysis vignette shipped alongside the interim power work. Housekeeping continues underneath, mostly clearing deprecated ggplot2 interfaces, aes_string in one release and qplot in the next.

◆ Prediction

Given the last two releases each added one method with a supporting vignette, expect the next to follow the same shape. Both additions so far extend the package beyond fixed dose-response fitting, so adaptive and interim methodology is the more likely direction.

O
OpenObserve
ANALYTICS
6.3

After its largest release, OpenObserve is patching the seams.

◆ Current state

v0.92.0 landed on 7 August with 836 commits and three new product surfaces - synthetic monitoring, Workflows v1, and an expanded AI observability set - after a long RC series. The two releases since are small: v0.92.1 fixed alert HAVING clause typing and put the MCP server setup page on the OSS build, and v0.92.2 adds a compactor delay setting and backports an MCP 404 fix for deployments running under a base URI. The 0.91 line is still receiving its own backports.

◆ Where it's heading

OpenObserve is trying to become the whole monitoring stack rather than the storage layer under one. Synthetic checks, incident workflows, and SLO measurement each replace a separate tool, and incident ingestion from external alert sources hedges the migration path for teams that cannot switch all at once. The MCP work running alongside - open sourced, then given a setup page in the OSS build, then fixed for base-URI deployments - shows the same data being aimed at agent clients rather than dashboards.

◆ Prediction

The post-GA patches are still landing on the new surfaces, so expect another 0.92.x before feature work resumes - most likely hardening synthetic monitoring and Workflows, which are the two least-exercised additions.

Alternatives to DoseFinding and OpenObserve

Other Analytics products tracked by Sparkpulse, ranked by recent ship velocity. Each card links to a full editorial trajectory and lets you pivot into a head-to-head comparison with either DoseFinding or OpenObserve.

See all DoseFinding alternatives → · See all OpenObserve alternatives →

Recent activity from DoseFinding and OpenObserve

Latest ship moves from both products, interleaved chronologically. ⚡ = editorial spark.

  1. 1d agoOpenObservev0.92.2: compactor delay setting and an MCP base-URI fix
  2. 5d agoOpenObservev0.92.1 brings the MCP server setup page to the OSS build
  3. 12d agoOpenObservev0.92.0 adds synthetic monitoring, workflows, and AI observability
  4. 12d agoOpenObserveRelease candidate 4 backports fixes before the v0.92.0 GA
  5. 14d agoOpenObserveRC3 adds agent-level filters and parallel zstd compression
  6. 20d agoOpenObservev0.91.5 patches an RBAC migration and a layout bug
  7. 1y agoDoseFindingConditional and predictive power for interim analyses
  8. 1y agoDoseFindingModel averaging arrives for dose-response fitting
  9. 1y agoDoseFindingPackage moves to openpharma under new maintainership
  10. 2y agoDoseFindingCompliance update for R-devel
  11. 3y agoDoseFindingpowMCTBinCount bug fix

Frequently asked questions

What is the difference between DoseFinding and OpenObserve?

They serve adjacent needs but don't currently overlap on shipped themes. OpenObserve is currently shipping more aggressively (velocity 6.3 vs 0.0), with 1 editorial sparks in the last 30 days against 0. See the at-a-glance table above for a side-by-side breakdown of velocity, recent sparks, and editorial themes.

Is DoseFinding better than OpenObserve?

Sparkpulse doesn't pick a winner — we score release velocity, not feature parity. OpenObserve is currently shipping more aggressively (velocity 6.3 vs 0.0), with 1 editorial sparks in the last 30 days against 0. For your specific use case, the alternatives sections above list other Analytics products to evaluate alongside.

What are the best alternatives to DoseFinding?

Top DoseFinding alternatives in Analytics are ranked by recent ship velocity. Browse the "DoseFinding alternatives" section above for the current picks, or visit /alternatives/dosefinding for the full list with editorial commentary on each.

What are the best alternatives to OpenObserve?

Top OpenObserve alternatives in Analytics are ranked by recent ship velocity. Browse the "OpenObserve alternatives" section above for the current picks, or visit /alternatives/openobserve for the full list with editorial commentary on each.